Liminal BioSciences To Sell Rare Pediatric Disease Priority Review Voucher For $105 Mln

Liminal BioSciences Inc. (LMNL) said that, its subsidiary Prometic Biotherapeutics Inc. or "PBT", agreed to sell its Rare Pediatric Disease Priority Review Voucher or "PRV" for US$105 million.

The PRV was granted by the U.S. Food and Drug Administration with the approval of Ryplazim (plasminogen, human-tvmh), for treatment of patients with plasminogen deficiency type 1 (hypoplasminogenia).

Under the terms of the previously announced Share Purchase Agreement entered into with Kedrion S.p.A dated June 22, 2021; Liminal Biosciences is entitled to retain an amount equal to 70% of the net sales proceeds of the sale of the PRV.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Cryptocurrency Dogecoin's price jumped over 15% on Friday, but later lost some of the gains, after Tesla Inc. (TSLA) CEO Elon Musk announced that the luxury car maker will start accepting the meme cryptocurrency as payment for its merchandise. "Tesla merch buyable with Dogecoin," Musk tweeted on Friday. Dogecoin... US investment bank JPMorgan Chase & Co. reported Friday a profit for the fourth quarter that declined 14 percent from last year, hurt primarily by higher noninterest expense and lower credit reserve releases. Both adjusted earnings per share and revenues for the quarter topped analysts' expectations. Microsoft Corp. said its Board of Directors has initiated a review of the effectiveness of its workplace sexual harassment and gender discrimination policies and practices. The company has hired the law firm of Arent Fox to conduct the review mainly on sexual harassment investigations, including that of co-founder Bill Gates.
Follow RTT